Advancements in targeted therapy for uterine cancer have shown promise in improving treatment outcomes, reducing side effects, and enhancing the quality of life for patients. Targeted therapy is a type of cancer treatment focusing on specific molecules or pathways involved in the growth and spread of cancer cells rather than broadly affecting rapidly dividing cells, as in traditional chemotherapy. Targeted therapies are drugs designed to target particular changes in cancer cells. They can be helpful for high-risk or advanced uterine cancer.
One of the key advancements in targeted therapy is the ability to perform molecular profiling of uterine tumors. This involves analyzing the genetic and molecular characteristics of the tumor to identify specific mutations or alterations that can be targeted. This allows a personalized treatment approach, as each patient's cancer may have different molecular features.
Access Full Report @ https://www.databridgemarketresearch.com/reports/global-uterine-cancer-drug-market
Data Bridge Market Research analyses that the Uterine Cancer Drugs Market is expected to grow with a CAGR of 8.5% in the forecast period from 2023 to 2030 and is expected to reach USD 4,269,049.34 thousand by 2030.
Key Findings of the Study
Growing R&D Activities for Uterine Cancer Treatment
Growing R&D activities for uterine cancer treatment represent a critical aspect of advancing medical science and improving patient outcomes. This increase in R&D activities reflects a deeper commitment to treat uterine cancer and develop more effective and targeted treatment strategies.
Researchers continually identify specific genetic mutations and molecular alterations associated with uterine cancer subtypes. These biomarkers help in tailoring treatment plans to individual patients and guiding clinicians in selecting therapies that are more likely to be effective. For instance, identifying PTEN mutations in certain endometrial cancers has led to more personalized treatment options.
Targeted therapies are a product of R&D efforts. These therapies address uterine cancer's specific genetic and molecular features. The development of drugs such as trastuzumab for HER2-positive uterine cancers demonstrates the potential of targeted treatments. The ongoing R&D is focused on expanding the range of available targeted therapies and increasing their effectiveness. Clinical trials play a central role in R&D for uterine cancer treatment. These trials investigate the safety and efficacy of new therapies and approaches. They provide patients with opportunities to access cutting-edge treatments while contributing to advancing medical knowledge. Ongoing trials focus on novel agents, combination therapies, and the assessment of treatment strategies based on genetic and molecular characteristics.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Thousand
|
|
Segments Covered
|
By Cancer Type (Endometrial Cancer and Uterine Sarcoma), Treatment Type (Chemotherapy, Hormone Therapy, Targeted Therapy, Immunotherapy, and Others), Drug Type (Generic and Branded), Age Group (Adults and Geriatric), Route of Administration (Oral and Parenteral), End User (Hospitals, Cancer Centers, Specialty Clinics, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, France, Italy, Spain, U.K., Switzerland, Netherlands, Russia, Turkey, Sweden, Belgium, rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Thailand, Indonesia, Malaysia, Philippines, rest Of Asia-Pacific, Brazil, Argentina, rest of South America, South Africa, U.A.E., Saudi Arabia, Kuwait, and rest of Middle East and Africa.
|
|
Market Players Covered
|
Baxter (U.S.), Accord BioPharma, Inc. (U.S.), Eli Lilly and Company (U.S.), Hikma Pharmaceuticals PLC (U.K.), Sun Pharmaceutical Industries Ltd.(India), Viatris Inc. (U.S.), Sanofi(France), Teva Pharmaceuticals USA, Inc. (Israel), Amneal Pharmaceuticals LLC (U.S.), Merck & Co., Inc. (U.S.), GSK plc. (U.K.), Eisai Co., Ltd.(Japan), Pfizer Inc. (U.S.), Virtus (U.S.), and Getwell Oncology (India) among others.
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis
The global uterine cancer drugs market is segmented into seven notable segments based on cancer type, treatment type, drug type, age group, route of administration, end-user, and distribution channel.
- On the basis of cancer type, the market is segmented into endometrial cancer and uterine sarcoma
In 2023, the endometrial cancer segment is expected to dominate the market.
In 2023, the endometrial cancer segment is expected to dominate the market due to rising incidences of uterine cancer worldwide with a market share of 83.25%.
- On the basis of treatment type, the market is segmented into chemotherapy, immunotherapy, hormone therapy, targeted therapy, and others
In 2023, the chemotherapy segment is expected to dominate the market.
In 2023, the chemotherapy segment is expected to dominate the market due to advancements in targeted therapy for uterine cancer with a market share of 61.97%.
- On the basis of drug type, the market is segmented into generic and branded. In 2023, the generics segment is expected to dominate the market with a market share of 61.30%
- On the basis of age group, the market is segmented into geriatric and adults. In 2023, the geriatric segment is expected to dominate the market with a market share of 73.43%
- On the basis of route of administration, the market is segmented into parenteral and oral. In 2023, the parenteral segment is expected to dominate the market with a market share of 68.22%
- On the basis of end-user, the market is segmented into hospitals, cancer centers, specialty clinics, and others. In 2023, the hospitals segment is expected to dominate the market with a market share of 43.06%
- On the basis of distribution channel, the market is segmented into direct tender, retail sales, and others. In 2023, the direct tender segment is expected to dominate the market with a market share of 54.89%
Major Players
Data Bridge Market Research analyses Sanofi (France), Teva Pharmaceuticals USA, Inc. (Israel), Merck & Co., Inc. (U.S.), Eisai Co., Ltd. (Japan), and Pfizer Inc. (U.S.) as the major players of the global uterine cancer drugs market.
Market Development
- In October 2023, Eli Lilly and Company (NYSE: LLY) announced that it was going to acquire POINT Biopharma Global, Inc. (NASDAQ: PNT). POINT Biopharma company has radiopharmaceuticals in its pre-clinical and clinical pipeline that are used to target multiple types of cancer precisely. This acquisition will help the company to Expand Oncology Capabilities into Next-Generation Radiolig and Therapies
- In October 2023, Merck and Co., Inc. introduced effects from the Phase three KEYNOTE-A39 trial (in addition referred to as EV-302), which was carried out in collaboration with Seagen and Astellas, comparing KEYTRUDA, Merck’s anti-PD-1 therapy, plus Padcev (enfortumab vedotin-ejfv), an antibody-drug conjugate, as compared to chemotherapy (gemcitabine plus cisplatin or carboplatin) in sufferers with formerly untreated domestically superior or metastatic urothelial carcinoma. The Phase three KEYNOTE-A39 trial is meant to function as the premise for international regulatory submissions and because the confirmatory trial for the modern-day U.S. extended approval of KEYTRUDA plus enfortumab vedotin as first-line remedy for sufferers with urothelial carcinoma who are not eligible to get hold of cisplatin-containing chemotherapy. This will help the company to expand the application of its brand KEYTRUDA
- In March 2023, Eisai Co., Ltd. announced the presentation of two abstracts at the Society of Gynaecologic Oncology (SGO) Women's Cancer 2023 Annual Meeting held in person in Tampa, Florida, and at the practice on March 25, 2023. Notable research to be featured in the Scientific Plenary IX: The Best of the Rest session includes a presentation of real-world outcomes and healthcare resource utilization in patients with recurrent or advanced endometrial carcinoma who were rechallenged with platinum chemotherapy in Europe. Also presented data from the LEAP (LEnvatinib And Pembrolizumab) clinical program, which analyzed tumor response to the arm of lenvatinib (LENVIMA) and pembrolizumab (KEYTRUDA) in the pivotal Phase 3 study 309/KEYNOTE-775 in patients with advanced endometrial carcinoma following at least one previous platinum-based regimen in any setting. This initiative by the company was to raise awareness about LENVIMA treating endometrial cancer
- In March 2023, Teva Pharmaceuticals, a subsidiary of Teva Pharmaceutical USA, Inc. and NATCO Pharma Limited USA subsidiary, announced the launch of the generic version of Revlimid (lenalidomide capsules) in additional strengths of 2.5 mg and 20 mg. The companies launched four additional product strengths in the U.S. market in March 2022. At launch, the companies made all strengths of Lenalidomide available in the U.S. market.
- In December 2022, Sanofi and Innate Pharma SA announced an expansion of their collaboration, with Sanofi licensing a Natural Killer (NK) cell engager program targeting B7H3 from Innate’s ANKETTM (Antibody-based NK Cell Engager Therapeutics) platform. Sanofi will also have the option to add up to two additional ANKETTM targets. It will be responsible for all development, manufacturing, and commercialization. This collaboration will help to expand sanofi’s oncology portfolio in the global market
Regional Analysis
Geographically, the countries covered in the global Uterine cancer drugs market report are the U.S., Canada, Mexico, Germany, France, Italy, Spain U.K., Switzerland, Netherlands, Russia, Turkey, Sweden, Belgium, rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Thailand, Indonesia, Malaysia, Philippines, rest of Asia-Pacific, Brazil, Argentina, rest of South America, South Africa, U.A.E., Saudi Arabia, Kuwait, rest of Middle East and Africa
As per Data Bridge Market Research analysis:
North America is the dominant region in the global uterine cancer drugs market.
North America is expected to dominate the market due to the high demand for Uterine cancer drugs in the region and the rise in healthcare expenditure. It will continue to dominate the market in terms of market share and revenue and will continue to flourish its dominance during the forecast period.
Asia-Pacific is estimated to be the fastest-growing region in global uterine cancer drugs market.
Asia-Pacific is estimated to be the fastest-growing region in the market for the forecast period 2023-2030 due to the growing adoption of advanced targeted therapy and the launch of new products in this region.
For more detailed information about the global uterine cancer drugs market report, click here – https://www.databridgemarketresearch.com/reports/global-uterine-cancer-drug-market
